Abstract
TAK-242 (resatorvid), a small-molecule–specific inhibitor of Toll-like receptor (TLR) 4 signaling, inhibits the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4. Cys747 in TLR4 has been identified previously as the binding site of TAK-242. However, the mechanism by which TAK-242 inhibits TLR4 signaling after binding to TLR4 remains unknown. The present study demonstrated, using coimmunoprecipitation, that TAK-242 interferes with protein-protein interactions between TLR4 and its adaptor molecules. Among 10 different human TLRs, TAK-242 selectively bound to TLR4. The time course of the inhibitory effect of TAK-242 on inflammatory mediator production corresponded to that of the binding of TAK-242 to TLR4. TAK-242 inhibited the association of TLR4 with Toll/interleukin-1 receptor domain-containing adaptor protein (TIRAP) or Toll/interleukin-1 receptor domain-containing adaptor protein inducing interferon-β-related adaptor molecule (TRAM) in human embryonic kidney (HEK) 293 cells overexpressing TLR4, MD-2, and TIRAP or TRAM, respectively. TAK-242 inhibited the TIRAP-mediated activation of nuclear factor κB (NF-κB) and the TRAM-mediated activation of NF-κB and interferon-sensitive response element in HEK293 cells stably expressing TLR4, MD-2, and CD14. The activation of endogenous interleukin-1 receptor-associated kinase in RAW264.7 cells was also inhibited by TAK-242 treatment. These findings suggest that TAK-242 binds selectively to TLR4 and subsequently disrupts the interaction of TLR4 with adaptor molecules, thereby inhibiting TLR4 signal transduction and its downstream signaling events. This work proposes a novel paradigm of a small molecule capable of disrupting protein-protein interactions.
Footnotes
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.110.068064.
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- TLR
- Toll-like receptor
- LPS
- lipopolysaccharide
- IL
- interleukin
- IFN
- interferon
- TNF
- tumor necrosis factor
- TIR
- Toll/interleukin-1 receptor
- MyD88
- myeloid differentiation primary response gene 88
- TIRAP
- Toll/interleukin-1 receptor domain-containing adaptor protein
- TRIF
- Toll/interleukin-1 receptor domain-containing adaptor protein inducing interferon-β
- TRAM
- Toll/interleukin-1 receptor domain-containing adaptor protein inducing interferon-β-related adaptor molecule
- IRAK
- interleukin-1 receptor-associated kinase
- HEK
- human embryonic kidney
- TAK-242 (resatorvid)
- ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate
- NF-κB
- nuclear factor-κB
- ISRE
- interferon-sensitive response element
- Ab
- antibody
- mAb
- monoclonal antibody
- PAGE
- polyacrylamide gel electrophoresis
- HA
- hemagglutinin
- FCS
- fetal calf serum
- DMEM
- Dulbecco's modified Eagle's medium
- TK
- thymidine kinase
- BAY 11-7082
- 3-[(4-methylphenyl)sulfonyl]-(2E)-propenenitrile
- SB203580
- 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole
- U0126
- 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene
- SP600125
- 1,9-pyrazoloanthrone.
- Received August 9, 2010.
- Accepted September 29, 2010.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|